4.4 Article

Osteoporosis and mortality

Journal

JOINT BONE SPINE
Volume 77, Issue -, Pages S107-S112

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/S1297-319X(10)70004-X

Keywords

Osteoporosis; Fractures; Mortality; Dose effect; Time effect

Categories

Funding

  1. MSD Lilly Novartis Servier Amgen Roche Wyeth Abbott
  2. MSD
  3. Lilly
  4. Novartis
  5. Amgen
  6. Roche
  7. Wyeth Abbott
  8. Servier

Ask authors/readers for more resources

Osteoporosis is classified as a public health problem by healthcare authorities because it is associated with an increased risk of potentially serious fractures Osteoporotic fractures are known to generate a heavy burden of morbidity and financial cost [1] However recent data indicate that some osteoporotic fractures are also associated with excess mortality These data have led to public health measures such as the addition by the World Health Organization of fracture prevention to the list of public health priorities [2] and the update on hip fractures issued recently by the statistics department of the French ministry of health (DREES [3]) Hip fractures constitute the most severe complication of osteoporosis because they can Induce permanent physical disability loss of self sufficiency institutionalization and above all an increased risk of death Interestingly two recent publications support the hypothesis that optimal osteoporosis management may affect the risk of death Here we will review the main data linking osteoporotic fractures overall (as opposed to hip fractures only) and mortality (C) 2010 Societe francaise de rhumatologie Published by Elsevier Masson SAS All rights reserved

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available